Brentuximab Vedotin
Click here to learn more about a late-stage investigational agent and active clinical trials
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
Enfortumab Vedotin
Click here to learn more about a late-stage investigational agent and active clinical trials
- Urothelial cancer
- Solid tumors
Tucatinib
Click here to learn more about a late-stage investigational agent and active clinical trials
- Breast cancer
- Solid tumors
Tisotumab Vedotin
Click here to learn more about a late-stage investigational agent and active clinical trials
- Gynecologic cancer
- Solid tumors
Ladiratuzumab Vedotin
Click here to learn more about a late-stage investigational agent and active clinical trials
- Breast cancer
- Solid tumors
Pipeline Wall
Click here to see our full development pipeline.
Interactive Pipeline
Explore our interactive pipeline kiosk to learn about our development programs. The kiosk provides an overview of each agent, its proposed mechanism of action, clinical trial information, and high-level study schema.
SEA-CD40
SEA-TGT
SEA-BCMA
SEA-CD70
SGN-CD228A
SGN-B6A
SGN-STNV
Clinical Trials Kiosk
Explore our clinical trials kiosk to learn about our active or enrolling clinical studies
Medical Info & Other Resources
Click into the medical information kiosk to request more information or schedule a meeting with one of our medical science liaisons.
Videos
Explore our video kiosk to learn more about how our late-stage investigational agents exert their efficacy.
The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Welcome to the Seagen Medical Affairs website!
Instructions
Click on any of the + icons to learn more about our virtual content.
For technical issues with our site or general inquiries.
PUBLICATIONS
Click here to learn more about our publications at this congress.
Corporate Sponsored Presentations
Abstract #/Title/Lead Author
Type/Session Category & Title
Session Time & Location
7528 / Brentuximab Vedotin ECHELON-1
Brentuximab vedotin with Chemotherapy in Adolescents and Young Adults (AYAs) with Stage III or IV Hodgkin Lymphoma: a Subgroup Analysis From the Phase 3 ECHELON-1 Study
H. Crosswell
Poster Presentation
Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
Friday, June 4, 2021
On demand, 9:00 am ET
TPS7571 / Brentuximab Vedotin SGN35-031 TIP
Brentuximab vedotin in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (SGN35-031, Trial in Progress)
N. Bartlett
Poster Presentation
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Friday, June 4, 2021
On demand, 9:00 am ET
4528 / Enfortumab Vedotin EV-103 Cohort A
Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC)
T. Friedlander
Poster Presentation
Genitourinary Cancer—Kidney and Bladder
Friday, June 4, 2021
On demand, 9:00 am ET
4524 / Enfortumab Vedotin EV-201 Cohort 2
Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort
B. McGregor
Poster Presentation
Genitourinary Cancer—Kidney and Bladder
Friday, June 4, 2021
On demand, 9:00 am ET
4539 / Enfortumab Vedotin EV-301
Quality of Life, Functioning, and Symptoms in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma From EV-301: A Randomized Phase 3 Trial of Enfortumab Vedotin vs Chemotherapy
R. Mamtani
Poster Presentation
Genitourinary Cancer—Kidney and Bladder
Friday, June 4, 2021
On demand, 9:00 am ET
TPS4587 / Enfortumab Vedotin EV-304 TIP
KEYNOTE-B15/EV-304: randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC) (Trial in Progress)
C. Hoimes
Poster Presentation
Friday, June 4, 2021
On demand, 9:00 am ET
1043 / Tucatinib HER2CLIMB
Updated Results of Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB)
G. Curigliano
Poster Presentation
Breast Cancer—Metastatic
Friday, June 4, 2021
On demand, 9:00 am ET
TPS315 / Tucatinib SGNTUC-019 TIP
SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations (Trial in Progress)
T. Stinchcombe
Poster Presentation
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Friday, June 4, 2021
On demand, 9:00 am ET
TPS1097 / Tucatinib HER2CLIMB-04 TIP
HER2CLIMB-04: Phase 2 open label trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ unresectable locally-advanced or metastatic breast cancer with and without brain metastases (HER2CLIMB-04, Trial in Progress)
I. Krop
Poster Presentation
Breast Cancer – Metastatic
Friday, June 4, 2021
On demand, 9:00 am ET
1044 / Tucatinib 380-IST-004
Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer
E. Stringor-Reasor
Poster Presentation
Breast Cancer – Metastatic
Friday, June 4, 2021
On demand, 9:00 am ET
TPS595 / Tucatinib CompassHER2 RD TIP
A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + Tucatinib/Placebo in Patients with Residual HER2-Positive Invasive Breast Cancer (Trial In Progress)
C. O’Sullivan
Poster Presentation
Breast Cancer—Local/Regional/Adjuvant
Friday, June 4, 2021
On demand, 9:00 am ET
TPS5596 / Tisotumab Vedotin innovaTV 301 TIP
Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer (innovaTV 301/ENGOT cx12/GOG 3057, Trial in Progress)
I. Vergote
Poster Presentation
Gynecologic Cancer
Friday, June 4, 2021
On demand, 9:00 am ET
TPS3144 / SGN-B6A SGNB6A-001 TIP
A Phase 1 Study of SGN-B6A, an Antibody-Drug Conjugate Targeting Integrin Beta-6, in Patients With Advanced Solid Tumors (SGNB6A-001, Trial in Progress)
A. Patnaik
Poster Presentation
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Friday, June 4, 2021
On demand, 9:00 am ET
TPS2657 / SEA-TGT SGNTGT-001 TIP
SGNTGT-001: A Phase 1 Study of SEATGT, an Effector-Function Enhanced Monoclonal Antibody (mAb), in Advanced Malignancies (Trial in Progress)
E. Garralda
Poster Presentation
Developmental Therapeutics—Immunotherapy
Friday, June 4, 2021
On demand, 9:00 am ET
USM/COR/2021/0017
What would you like to do?
